Why did CVS report a large GAAP loss when adjusted EPS grew strongly?

The GAAP loss of $3.13 per share was driven mainly by a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit, which is a non-cash charge after management cut its growth projections for clinics. Adjusted EPS excludes this charge, amortization of intangibles, and other one-time items, which is why it rose to $1.60 from $1.09. Investors should weigh both measures, since the impairment reflects a real reduction in the value of the clinic business.

How sustainable is the improvement in Health Care Benefits profitability?

Part of the improvement is durable, including better Government business performance and the lapping of prior-year pressure. However, the quarter also benefited from favorable prior-period claims development of $1.9 billion year to date and favorable premium deficiency reserve movements, which do not necessarily repeat. Higher individual exchange acuity and Medicare Part D seasonality under the Inflation Reduction Act are headwinds. Investors should monitor MBR trends in future quarters to judge the underlying trajectory.

Why did CVS raise adjusted EPS guidance but lower GAAP EPS guidance?

The guidance change reflects the $5.7 billion goodwill impairment, the $1.2 billion legacy litigation charges, the loss on Accountable Care assets, and other excluded items that reduce GAAP earnings but are not included in adjusted EPS. Operating performance in the Health Care Benefits and Pharmacy & Consumer Wellness segments improved enough to lift the adjusted EPS range by about $0.25 at the midpoint, while the Health Services segment weakened.

What is the outlook for the Health Services and retail pharmacy businesses?

Health Services adjusted operating income declined 7.0% in the quarter, reflecting continued pharmacy client price improvements that offset better purchasing economics, and pharmacy claims processed fell 1.8%. Pharmacy & Consumer Wellness adjusted operating income fell 7.4% under reimbursement pressure, although prescription volume rose 6.9%, helped by the Rite Aid prescription file acquisitions and same-store volume growth of 8.9%. These trends suggest continued margin pressure in PBM and retail pharmacy, which investors should consider when evaluating the segments.

What changes are happening with the Health Care Delivery business?

Management said the Health Care Delivery unit, which includes Oak Street Health, has not grown at the rate previously expected. The company replaced parts of the management team, will open fewer new primary care clinics in 2026 and beyond, and plans to close certain Oak Street clinics in 2026, which led to an $83 million clinic closure charge. This marks a strategic pullback from the earlier expansion and a write-down of the acquired asset value, which raises questions about the return on the Oak Street and Signify acquisitions.

CVS 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.

CVS Health reported third-quarter 2025 results on October 29, 2025, with a headline GAAP loss that was driven almost entirely by a non-cash charge.

GAAP diluted loss per share was $3.13^a, against earnings of $0.07 a year earlier. The result included a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit (Oak Street Health and related clinics) and a $483 million gain on the deconsolidation of Omnicare, which entered Chapter 11 in September. Total revenue rose 7.8% to a record $102.9 billion, and adjusted EPS rose 47% to $1.60 from $1.09.

Adjusted operating income increased 35.8% to $3.46 billion^b, led by a sharp turnaround in Health Care Benefits, where adjusted operating income moved from a $924 million loss to $314 million and the medical benefit ratio improved about 240 basis points to 92.8%. Part of that improvement reflected favorable prior-period reserve development of $1.9 billion year to date and a favorable swing in premium deficiency reserves, so investors should treat some of the margin gain as non-recurring. The company raised its full-year 2025 adjusted EPS guidance to $6.55–$6.65 from $6.30–$6.40 and raised operating cash flow guidance to $7.5–$8.0 billion.

It cut GAAP EPS guidance to a loss of $(0.34) to $(0.24) from earnings of $3.84^c–$3.94, reflecting the goodwill charge and other excluded items. Year-to-date operating cash flow was $7.2 billion, flat year over year, while accounts receivable grew $7.5 billion, and goodwill fell to $85.5 billion. Management also said it plans fewer new primary care clinics in 2026 and beyond and will close certain Oak Street clinics, signaling a retreat from the Health Care Delivery build-out.

The Health Services segment is the main drag. Adjusted operating income fell 7.0%^d on continued client price concessions, and pharmacy claims processed declined 1.8%.

Pharmacy & Consumer Wellness adjusted operating income fell 7.4% under reimbursement pressure, even as prescriptions filled rose 6.9%, helped by the Rite Aid prescription file acquisitions. Overall, the quarter shows operational stabilization in the insurance business, but the GAAP results, the Health Care Delivery write-down, and the pressure in PBM and retail pharmacy warrant close attention.

02—Key points

Key Highlights

GAAP diluted loss per share of $3.13 versus $0.07 earnings in Q3 2024, driven by a $5.7 billion non-cash goodwill impairment on the Health Care Delivery reporting unit.
Adjusted EPS of $1.60, up 47% from $1.09, with adjusted operating income up 35.8% to $3.46 billion.
Record quarterly total revenue of $102.9 billion, up 7.8% year over year, with growth in all operating segments.
Health Care Benefits turned profitable on an adjusted basis ($314 million versus a $924 million loss), with MBR improving to 92.8% from 95.2%, though aided by $1.9 billion of favorable prior-year reserve development year to date.
Full-year 2025 adjusted EPS guidance raised to $6.55–$6.65 and operating cash flow guidance raised to $7.5–$8.0 billion, while GAAP EPS guidance was lowered to a loss of $(0.34) to $(0.24).
Health Services adjusted operating income fell 7.0% due to pharmacy client price concessions, and Pharmacy & Consumer Wellness adjusted operating income fell 7.4% on reimbursement pressure.
Omnicare's Chapter 11 filing led to deconsolidation with a $483 million gain, and the company is scaling back new primary care clinic openings and closing certain Oak Street clinics in 2026.

03—Questions

Frequently Asked Questions

Why did CVS report a large GAAP loss when adjusted EPS grew strongly?
The GAAP loss of $3.13 per share was driven mainly by a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit, which is a non-cash charge after management cut its growth projections for clinics. Adjusted EPS excludes this charge, amortization of intangibles, and other one-time items, which is why it rose to $1.60 from $1.09. Investors should weigh both measures, since the impairment reflects a real reduction in the value of the clinic business.
How sustainable is the improvement in Health Care Benefits profitability?
Part of the improvement is durable, including better Government business performance and the lapping of prior-year pressure. However, the quarter also benefited from favorable prior-period claims development of $1.9 billion year to date and favorable premium deficiency reserve movements, which do not necessarily repeat. Higher individual exchange acuity and Medicare Part D seasonality under the Inflation Reduction Act are headwinds. Investors should monitor MBR trends in future quarters to judge the underlying trajectory.
Why did CVS raise adjusted EPS guidance but lower GAAP EPS guidance?
The guidance change reflects the $5.7 billion goodwill impairment, the $1.2 billion legacy litigation charges, the loss on Accountable Care assets, and other excluded items that reduce GAAP earnings but are not included in adjusted EPS. Operating performance in the Health Care Benefits and Pharmacy & Consumer Wellness segments improved enough to lift the adjusted EPS range by about $0.25 at the midpoint, while the Health Services segment weakened.
What is the outlook for the Health Services and retail pharmacy businesses?
Health Services adjusted operating income declined 7.0% in the quarter, reflecting continued pharmacy client price improvements that offset better purchasing economics, and pharmacy claims processed fell 1.8%. Pharmacy & Consumer Wellness adjusted operating income fell 7.4% under reimbursement pressure, although prescription volume rose 6.9%, helped by the Rite Aid prescription file acquisitions and same-store volume growth of 8.9%. These trends suggest continued margin pressure in PBM and retail pharmacy, which investors should consider when evaluating the segments.
What changes are happening with the Health Care Delivery business?
Management said the Health Care Delivery unit, which includes Oak Street Health, has not grown at the rate previously expected. The company replaced parts of the management team, will open fewer new primary care clinics in 2026 and beyond, and plans to close certain Oak Street clinics in 2026, which led to an $83 million clinic closure charge. This marks a strategic pullback from the earlier expansion and a write-down of the acquired asset value, which raises questions about the return on the Oak Street and Signify acquisitions.

04—Continue

← View all 8-K filings